<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00261924</url>
  </required_header>
  <id_info>
    <org_study_id>451-P-A-NIV</org_study_id>
    <nct_id>NCT00261924</nct_id>
  </id_info>
  <brief_title>Efficacy and Safety Study of Platelets Treated for Pathogen Inactivation and Stored for Up to Seven Days</brief_title>
  <acronym>TESSI</acronym>
  <official_title>Clinical Trial to Evaluate the Therapeutic Efficacy and Safety of INTERCEPT Platelets Stored for up to Seven Days After Collection</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Cerus Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Cerus Corporation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Objective: To determine if platelets treated for pathogen inactivation and stored for 6 to 7&#xD;
      days are safe and effective compared to platelets collected by the same method, stored for&#xD;
      the same amount of time and not treated for pathogen inactivation.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Although the European Commission directive 2004/33/EC states that platelet preparations may&#xD;
      be stored for 7 days in conjunction with detection or reduction of bacterial contamination,&#xD;
      most blood centers store platelets for only 4 or 5 days. Extending the storage time could&#xD;
      greatly improve platelet availability for patients while decreasing wastage of this limited&#xD;
      resource.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2005</start_date>
  <completion_date type="Actual">July 2009</completion_date>
  <primary_completion_date type="Actual">July 2009</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1 hour corrected count increment for platelets</measure>
    <time_frame>One hour after platelet transfusion</time_frame>
    <description>1-h CCI</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Transfusion related adverse events</measure>
    <time_frame>24 hours after transfusion</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">211</enrollment>
  <condition>Thrombocytopenia</condition>
  <arm_group>
    <arm_group_label>Intercept Platelets</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Study patients receiving platelets that have been processed with the INTERCEPT pathogen inactivation system</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional Platelets</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Study patients receiving platelets processed by standard method without the INTERCEPT pathogen inactivation system</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transfusion of Pathogen Inactivated Platelets stored for 6-7 days</intervention_name>
    <description>pathogen inactivation of platelets for transfusion</description>
    <arm_group_label>Conventional Platelets</arm_group_label>
    <arm_group_label>Intercept Platelets</arm_group_label>
    <other_name>INTERCEPT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  At least 16 years old&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Thrombocytopenia, or expected to develop thrombocytopenia requiring platelet&#xD;
             transfusion within 15 days of randomization&#xD;
&#xD;
          -  Undergoing one haematopoietic stem cell transplantation and/or admitted for treatment&#xD;
             of acute or chronic leukaemia, lymphoma, multiple myeloma or myelodysplasia&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Refractoriness to platelet transfusion&#xD;
&#xD;
          -  Immune-mediated thrombocytopenia, thrombotic thrombocytopenic purpura, or hemolytic&#xD;
             uremic syndrome&#xD;
&#xD;
          -  Use of IL-11 (NeumegaÂ®) or other investigational platelet growth factor&#xD;
&#xD;
          -  Disseminated intravascular coagulation (DIC)&#xD;
&#xD;
          -  Clinically or radiologically detectable splenomegaly&#xD;
&#xD;
          -  Previous participation in the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Larry Corash, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Cerus Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>SNBTS National Science Laboratory, Edinburgh and Western General Hospital</name>
      <address>
        <city>Edinburgh</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>December 2005</verification_date>
  <study_first_submitted>December 5, 2005</study_first_submitted>
  <study_first_submitted_qc>December 5, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 6, 2005</study_first_posted>
  <last_update_submitted>April 13, 2010</last_update_submitted>
  <last_update_submitted_qc>April 13, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 14, 2010</last_update_posted>
  <responsible_party>
    <name_title>William Reed/ Director, Clinical Research Medical Affairs</name_title>
    <organization>Cerus</organization>
  </responsible_party>
  <keyword>Thrombocytopenic patients</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Thrombocytopenia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

